NCT01524809View on ClinicalTrials.gov

Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

June 30, 2001

Study Completion Date

June 30, 2001

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

biphasic insulin aspart 30

Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.

DRUG

biphasic insulin aspart 70

Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.

Trial Locations (1)

8000

Novo Nordisk Investigational Site, Århus C

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY